JP2018522869A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522869A5 JP2018522869A5 JP2017567737A JP2017567737A JP2018522869A5 JP 2018522869 A5 JP2018522869 A5 JP 2018522869A5 JP 2017567737 A JP2017567737 A JP 2017567737A JP 2017567737 A JP2017567737 A JP 2017567737A JP 2018522869 A5 JP2018522869 A5 JP 2018522869A5
- Authority
- JP
- Japan
- Prior art keywords
- pyridin
- chloro
- acetamido
- cyclohexanecarboxamide
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 39
- PNZXMIKHJXIPEK-UHFFFAOYSA-N cyclohexanecarboxamide Chemical compound NC(=O)C1CCCCC1 PNZXMIKHJXIPEK-UHFFFAOYSA-N 0.000 claims 28
- -1 4- (5,5-Dimethyl-5,6-dihydro-4H-pyrrolo [1,2-b] pyrazol-3-yl) pyridin-2-yl Chemical group 0.000 claims 27
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 27
- 125000004429 atom Chemical group 0.000 claims 24
- 125000000217 alkyl group Chemical group 0.000 claims 20
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 19
- 125000000753 cycloalkyl group Chemical group 0.000 claims 13
- 125000001309 chloro group Chemical group Cl* 0.000 claims 12
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 238000000634 powder X-ray diffraction Methods 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 229910052740 iodine Inorganic materials 0.000 claims 3
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 150000001204 N-oxides Chemical class 0.000 claims 2
- 229910004013 NO 2 Inorganic materials 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- GXHAENUAJYZNOA-UHFFFAOYSA-N oxolane-2-carboxamide Chemical compound NC(=O)C1CCCO1 GXHAENUAJYZNOA-UHFFFAOYSA-N 0.000 claims 2
- DUXPFRRFZLRICX-UHFFFAOYSA-N oxolane-3-carboxamide Chemical compound NC(=O)C1CCOC1 DUXPFRRFZLRICX-UHFFFAOYSA-N 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- YJEYKYGHJYFILG-LSDHHAIUSA-N (1S,3R)-3-acetamido-N-[5-chloro-4-[5-(3-hydroxy-2,2-dimethylpropyl)-1H-pyrazol-4-yl]pyridin-2-yl]cyclohexane-1-carboxamide Chemical compound C(C)(=O)N[C@H]1C[C@H](CCC1)C(=O)NC1=NC=C(C(=C1)C=1C=NNC=1CC(CO)(C)C)Cl YJEYKYGHJYFILG-LSDHHAIUSA-N 0.000 claims 1
- NVSCDXMDWYJJJH-GCKMJXCFSA-N (2R)-N-[(1R,3S)-3-[[5-chloro-4-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl)pyridin-2-yl]carbamoyl]cyclohexyl]oxolane-2-carboxamide Chemical compound ClC=1C(=CC(=NC=1)NC(=O)[C@@H]1C[C@@H](CCC1)NC(=O)[C@@H]1OCCC1)C=1C=NN2C=1CCCC2 NVSCDXMDWYJJJH-GCKMJXCFSA-N 0.000 claims 1
- NVSCDXMDWYJJJH-MRUHUIDDSA-N (2S)-N-[(1R,3S)-3-[[5-chloro-4-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl)pyridin-2-yl]carbamoyl]cyclohexyl]oxolane-2-carboxamide Chemical compound ClC=1C(=CC(=NC=1)NC(=O)[C@@H]1C[C@@H](CCC1)NC(=O)[C@H]1OCCC1)C=1C=NN2C=1CCCC2 NVSCDXMDWYJJJH-MRUHUIDDSA-N 0.000 claims 1
- OSSQKZBCEPPMTF-GVDBMIGSSA-N (3R)-N-[(1R,3S)-3-[[5-chloro-4-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl)pyridin-2-yl]carbamoyl]cyclohexyl]oxolane-3-carboxamide Chemical compound ClC=1C(=CC(=NC=1)NC(=O)[C@@H]1C[C@@H](CCC1)NC(=O)[C@H]1COCC1)C=1C=NN2C=1CCCC2 OSSQKZBCEPPMTF-GVDBMIGSSA-N 0.000 claims 1
- CNQYPEDWYADSGM-GFCCVEGCSA-N (3R)-N-[5-chloro-4-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl)pyridin-2-yl]piperidine-3-carboxamide Chemical compound ClC=1C(=CC(=NC=1)NC(=O)[C@H]1CNCCC1)C=1C=NN2C=1CCCC2 CNQYPEDWYADSGM-GFCCVEGCSA-N 0.000 claims 1
- NZWRCNMQLYTEDE-GFCCVEGCSA-N (3R)-N-[5-chloro-4-(5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-3-yl)pyridin-2-yl]piperidine-3-carboxamide Chemical compound ClC=1C(=CC(=NC=1)NC(=O)[C@H]1CNCCC1)C1=CN=C2N1CCCC2 NZWRCNMQLYTEDE-GFCCVEGCSA-N 0.000 claims 1
- OSSQKZBCEPPMTF-YESZJQIVSA-N (3S)-N-[(1R,3S)-3-[[5-chloro-4-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl)pyridin-2-yl]carbamoyl]cyclohexyl]oxolane-3-carboxamide Chemical compound ClC=1C(=CC(=NC=1)NC(=O)[C@@H]1C[C@@H](CCC1)NC(=O)[C@@H]1COCC1)C=1C=NN2C=1CCCC2 OSSQKZBCEPPMTF-YESZJQIVSA-N 0.000 claims 1
- LBHMIEZEXWDBJU-UHFFFAOYSA-N 1-hydroxycyclopropane-1-carboxamide Chemical compound NC(=O)C1(O)CC1 LBHMIEZEXWDBJU-UHFFFAOYSA-N 0.000 claims 1
- KJTRXVXWSSPHRV-UHFFFAOYSA-N 4-benzoyl-5-methyl-2-phenyl-1h-pyrazol-3-one Chemical compound O=C1C(C(=O)C=2C=CC=CC=2)=C(C)NN1C1=CC=CC=C1 KJTRXVXWSSPHRV-UHFFFAOYSA-N 0.000 claims 1
- XSTHAMSNEGCYGK-UHFFFAOYSA-N 5,5-dimethyl-4,6-dihydropyrrolo[1,2-b]pyrazole Chemical compound C1=NN2CC(C)(C)CC2=C1 XSTHAMSNEGCYGK-UHFFFAOYSA-N 0.000 claims 1
- NWHGYDOVVZZJLR-UHFFFAOYSA-N CC1(CC=2N(N=CC=2C2=CC(=NC=C2)C2(CC(C2)O)C(=O)N)C1)C Chemical compound CC1(CC=2N(N=CC=2C2=CC(=NC=C2)C2(CC(C2)O)C(=O)N)C1)C NWHGYDOVVZZJLR-UHFFFAOYSA-N 0.000 claims 1
- 101100240516 Caenorhabditis elegans nhr-10 gene Proteins 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- BNMSUGRKZJRLFE-FUHWJXTLSA-N N-[(1R,3S)-3-[[4-(5,5-dimethyl-4,6-dihydropyrrolo[1,2-b]pyrazol-3-yl)-5-methylpyridin-2-yl]carbamoyl]cyclohexyl]oxetane-3-carboxamide Chemical compound CC1(CC=2N(N=CC=2C2=CC(=NC=C2C)NC(=O)[C@@H]2C[C@@H](CCC2)NC(=O)C2COC2)C1)C BNMSUGRKZJRLFE-FUHWJXTLSA-N 0.000 claims 1
- XJDSFHHHUIAIDM-FUHWJXTLSA-N N-[(1R,3S)-3-[[4-(5,5-dimethyl-4,6-dihydropyrrolo[1,2-b]pyrazol-3-yl)pyridin-2-yl]carbamoyl]cyclohexyl]oxetane-3-carboxamide Chemical compound CC1(CC=2N(N=CC=2C2=CC(=NC=C2)NC(=O)[C@@H]2C[C@@H](CCC2)NC(=O)C2COC2)C1)C XJDSFHHHUIAIDM-FUHWJXTLSA-N 0.000 claims 1
- VBGGKLUDOCLBMG-JKSUJKDBSA-N N-[(1R,3S)-3-[[5-chloro-4-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl)pyridin-2-yl]carbamoyl]cyclohexyl]-3-methyloxetane-3-carboxamide Chemical compound ClC=1C(=CC(=NC=1)NC(=O)[C@@H]1C[C@@H](CCC1)NC(=O)C1(COC1)C)C=1C=NN2C=1CCCC2 VBGGKLUDOCLBMG-JKSUJKDBSA-N 0.000 claims 1
- ADCMLAZAXQVHRQ-GOEBONIOSA-N N-[(1R,3S)-3-[[5-chloro-4-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl)pyridin-2-yl]carbamoyl]cyclohexyl]oxetane-3-carboxamide Chemical compound ClC=1C(=CC(=NC=1)NC(=O)[C@@H]1C[C@@H](CCC1)NC(=O)C1COC1)C=1C=NN2C=1CCCC2 ADCMLAZAXQVHRQ-GOEBONIOSA-N 0.000 claims 1
- XNBVUZHSZXDHAY-GOEBONIOSA-N N-[(1R,3S)-3-[[5-chloro-4-(5,5-dimethyl-4,6-dihydropyrrolo[1,2-b]pyrazol-3-yl)pyridin-2-yl]carbamoyl]cyclohexyl]oxetane-3-carboxamide Chemical compound ClC=1C(=CC(=NC=1)NC(=O)[C@@H]1C[C@@H](CCC1)NC(=O)C1COC1)C1=C2N(N=C1)CC(C2)(C)C XNBVUZHSZXDHAY-GOEBONIOSA-N 0.000 claims 1
- ONDUAKFQKLPDKJ-GOEBONIOSA-N N-[(1R,3S)-3-[[5-chloro-4-(6,6-dimethyl-5,7-dihydropyrrolo[1,2-a]imidazol-3-yl)pyridin-2-yl]carbamoyl]cyclohexyl]oxetane-3-carboxamide Chemical compound ClC=1C(=CC(=NC=1)NC(=O)[C@@H]1C[C@@H](CCC1)NC(=O)C1COC1)C1=CN=C2N1CC(C2)(C)C ONDUAKFQKLPDKJ-GOEBONIOSA-N 0.000 claims 1
- HGQOZUXBCVGHDO-UHFFFAOYSA-N N-[4-(5,5-dimethyl-4,6-dihydropyrrolo[1,2-b]pyrazol-3-yl)-5-fluoropyridin-2-yl]cyclohexanecarboxamide Chemical compound C1(CCCCC1)C(=O)NC1=NC=C(C(=C1)C1=C2N(N=C1)CC(C2)(C)C)F HGQOZUXBCVGHDO-UHFFFAOYSA-N 0.000 claims 1
- QUXGAYIZHOSKAB-UHFFFAOYSA-N N-[5-chloro-4-(4,5,6,7-tetrahydrotriazolo[1,5-a]pyridin-3-yl)pyridin-2-yl]cyclohexanecarboxamide Chemical compound C1(CCCCC1)C(=O)NC1=NC=C(C(=C1)C=1N=NN2C=1CCCC2)Cl QUXGAYIZHOSKAB-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562185852P | 2015-06-29 | 2015-06-29 | |
| US62/185,852 | 2015-06-29 | ||
| PCT/EP2016/064899 WO2017001354A1 (en) | 2015-06-29 | 2016-06-27 | Polycyclic amide derivatives as cdk9 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018522869A JP2018522869A (ja) | 2018-08-16 |
| JP2018522869A5 true JP2018522869A5 (enExample) | 2019-07-18 |
| JP6997627B2 JP6997627B2 (ja) | 2022-01-17 |
Family
ID=56292699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017567737A Active JP6997627B2 (ja) | 2015-06-29 | 2016-06-27 | Ｃｄｋ９阻害剤としての多環式アミド誘導体 |
Country Status (38)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200289506A1 (en) | 2017-09-25 | 2020-09-17 | Astrazeneca Ab | Combination of a btk inhibitor and an inhibitor or cdk9 to treat cancer |
| EP3694506B1 (en) | 2017-10-09 | 2023-08-02 | Merck Sharp & Dohme LLC | Novel substituted phenyloxetane and phenyltetrahydrofuran compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
| CN108129288B (zh) * | 2017-12-27 | 2021-01-22 | 上海毕得医药科技股份有限公司 | 一种反式-3-羟基环丁基甲酸的合成方法 |
| TWI810397B (zh) | 2018-11-14 | 2023-08-01 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
| WO2020259556A1 (zh) * | 2019-06-27 | 2020-12-30 | 南京明德新药研发有限公司 | 作为cdk9抑制剂的氮杂吲哚连吡唑类化合物 |
| CA3153531A1 (en) | 2019-09-11 | 2021-03-18 | Prelude Therapeutics Incorporated | Cdk inhibitors and their use as pharmaceuticals |
| WO2021115335A1 (zh) * | 2019-12-09 | 2021-06-17 | 石药集团中奇制药技术（石家庄）有限公司 | 作为周期蛋白依赖性激酶9抑制剂的化合物及其应用 |
| WO2021227906A1 (zh) | 2020-05-12 | 2021-11-18 | 苏州阿尔脉生物科技有限公司 | 一种作为cdk抑制剂的吡啶乙酰胺类衍生物、其制备方法及用途 |
| CN113149996B (zh) * | 2020-05-12 | 2022-12-20 | 苏州阿尔脉生物科技有限公司 | 一种作为cdk9抑制剂的多环酰胺类衍生物、其制备方法及用途 |
| US20230233540A1 (en) * | 2020-06-24 | 2023-07-27 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and cdk9 inhibitor |
| WO2022028556A1 (zh) | 2020-08-07 | 2022-02-10 | 南京药石科技股份有限公司 | Cdk9抑制剂及其用途 |
| TWI809330B (zh) * | 2020-11-20 | 2023-07-21 | 大陸商勁方醫藥科技(上海)有限公司 | Cdk9抑制劑的多晶型物及其製法和用途 |
| CN115381824B (zh) * | 2021-05-24 | 2024-11-05 | 石药集团中奇制药技术（石家庄）有限公司 | 周期蛋白依赖性激酶9抑制剂的用途 |
| WO2022247785A1 (zh) * | 2021-05-24 | 2022-12-01 | 石药集团中奇制药技术（石家庄）有限公司 | 一种周期蛋白依赖性激酶9抑制剂的用途 |
| CN117813289A (zh) * | 2021-07-14 | 2024-04-02 | 上海海雁医药科技有限公司 | 吡唑衍生物及其中间体和制备方法 |
| CN115703738B (zh) * | 2021-08-16 | 2024-06-21 | 中国科学院上海药物研究所 | 含2-芳杂环取代的脲类化合物、其制备方法和用途 |
| AU2022419653A1 (en) * | 2021-12-23 | 2024-07-18 | Katholieke Universiteit Leuven | Tetrahydropyrazolopyrimidines and related analogs for inhibiting yap/taz-tead |
| AU2023326499A1 (en) | 2022-08-17 | 2025-03-27 | Korea Research Institute Of Bioscience And Biotechnology | Compounds for inhibiting or decomposing cdk2 and/or cdk9, and medicinal uses thereof |
| CN117659022A (zh) * | 2022-09-06 | 2024-03-08 | 苏州阿尔脉生物科技有限公司 | 脲基取代吡啶类化合物、包含其的药物组合物及其医药用途 |
| WO2024220876A1 (en) * | 2023-04-19 | 2024-10-24 | Alcon Inc. | N-substituted c6 cyclyl carboxamide compounds and uses thereof |
| WO2025076115A1 (en) * | 2023-10-02 | 2025-04-10 | Prelude Therapeutics Incorporated | Cdk inhibitors and their use as pharmaceuticals |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008133192A1 (ja) | 2007-04-19 | 2008-11-06 | Takeda Pharmaceutical Company Limited | 縮合イミダゾール化合物およびその用途 |
| ES2539518T3 (es) | 2007-04-24 | 2015-07-01 | Astrazeneca Ab | Inhibidores de proteínas quinasas |
| JP5379787B2 (ja) | 2007-04-24 | 2013-12-25 | インゲニウム ファーマシューティカルズ ジーエムビーエイチ | プロテインキナーゼの阻害剤 |
| US8507498B2 (en) | 2007-04-24 | 2013-08-13 | Ingenium Pharmaceuticals Gmbh | 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases |
| JP5566879B2 (ja) | 2007-04-24 | 2014-08-06 | インゲニウム ファーマシューティカルズ ジーエムビーエイチ | プロテインキナーゼの阻害剤 |
| WO2008132138A1 (en) | 2007-04-25 | 2008-11-06 | Ingenium Pharmaceuticals Gmbh | Derivatives of 4,6-disubstituted aminopyrimidines |
| NZ584454A (en) | 2007-10-12 | 2011-09-30 | Ingenium Pharmaceuticals Gmbh | N-[6-phenyl-pyrimidin-4-yl]-amides and urea derivatives as inhibitors of protein kinases |
| AU2010291212A1 (en) | 2009-09-04 | 2012-02-23 | Novartis Ag | Heteroaryl compounds as kinase inhibitors |
| US20110113038A1 (en) | 2009-11-12 | 2011-05-12 | International Business Machines Corporation | Search term security |
| GB201002911D0 (en) | 2010-02-19 | 2010-04-07 | Medical Res Council | Compound |
| NZ627520A (en) | 2010-03-10 | 2015-10-30 | Astrazeneca Ab | 4-phenyl pyridine analogues as protein kinase inhibitors |
| AR081810A1 (es) | 2010-04-07 | 2012-10-24 | Bayer Cropscience Ag | Piridinilpirazoles biciclicos |
| WO2012066065A1 (en) | 2010-11-17 | 2012-05-24 | Novartis Ag | Phenyl-heteroaryl amine compounds and their uses |
| WO2012101063A1 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyridine biaryl compounds and their uses |
| WO2012101064A1 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyrimidine biaryl compounds as protein kinase inhibitors |
| CN103339110A (zh) * | 2011-01-28 | 2013-10-02 | 诺瓦提斯公司 | 作为cdk9抑制剂的取代的杂-联芳基化合物及其用途 |
| RU2627272C2 (ru) | 2011-10-06 | 2017-08-04 | Байер Интеллектчуал Проперти Гмбх | Гетероциклилпиридинилпиразолы |
| WO2014159999A1 (en) | 2013-03-13 | 2014-10-02 | Abbvie Inc. | Cdk9 kinase inhibitors |
| CN105189481A (zh) | 2013-03-13 | 2015-12-23 | 艾伯维公司 | 吡啶cdk9激酶抑制剂 |
| WO2014139328A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors |
| CA2903538A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | Pyrrolopyrimindine cdk9 kinase inhibitors |
-
2016
- 2016-06-27 CA CA2989499A patent/CA2989499C/en active Active
- 2016-06-27 EA EA201890094A patent/EA035383B1/ru not_active IP Right Cessation
- 2016-06-27 TN TNP/2017/000486A patent/TN2017000486A1/en unknown
- 2016-06-27 ME MEP-2019-138A patent/ME03404B/me unknown
- 2016-06-27 SI SI201630247T patent/SI3313838T1/sl unknown
- 2016-06-27 TR TR2019/09286T patent/TR201909286T4/tr unknown
- 2016-06-27 LT LTEP16733459.8T patent/LT3313838T/lt unknown
- 2016-06-27 EP EP19165726.1A patent/EP3539961B1/en active Active
- 2016-06-27 SM SM20190298T patent/SMT201900298T1/it unknown
- 2016-06-27 HR HRP20190748TT patent/HRP20190748T1/hr unknown
- 2016-06-27 HU HUE19165726A patent/HUE057343T2/hu unknown
- 2016-06-27 HR HRP20211970TT patent/HRP20211970T1/hr unknown
- 2016-06-27 EP EP16733459.8A patent/EP3313838B1/en active Active
- 2016-06-27 PE PE2017002874A patent/PE20180530A1/es unknown
- 2016-06-27 US US15/193,826 patent/US9845331B2/en active Active
- 2016-06-27 KR KR1020187002262A patent/KR102663113B1/ko active Active
- 2016-06-27 SM SM20220005T patent/SMT202200005T1/it unknown
- 2016-06-27 RS RS20190564A patent/RS58712B1/sr unknown
- 2016-06-27 AU AU2016286200A patent/AU2016286200B2/en active Active
- 2016-06-27 HU HUE16733459A patent/HUE043440T2/hu unknown
- 2016-06-27 CN CN201680029447.9A patent/CN107873028B/zh active Active
- 2016-06-27 BR BR122019013677-7A patent/BR122019013677B1/pt active IP Right Grant
- 2016-06-27 DK DK19165726.1T patent/DK3539961T3/da active
- 2016-06-27 PL PL16733459T patent/PL3313838T3/pl unknown
- 2016-06-27 ES ES19165726T patent/ES2902148T3/es active Active
- 2016-06-27 PH PH1/2017/502334A patent/PH12017502334B1/en unknown
- 2016-06-27 WO PCT/EP2016/064899 patent/WO2017001354A1/en not_active Ceased
- 2016-06-27 PT PT16733459T patent/PT3313838T/pt unknown
- 2016-06-27 CR CR20210297A patent/CR20210297A/es unknown
- 2016-06-27 SI SI201631427T patent/SI3539961T1/sl unknown
- 2016-06-27 ES ES16733459T patent/ES2728356T3/es active Active
- 2016-06-27 MY MYPI2017705054A patent/MY201673A/en unknown
- 2016-06-27 PT PT191657261T patent/PT3539961T/pt unknown
- 2016-06-27 CR CR20170596A patent/CR20170596A/es unknown
- 2016-06-27 MX MX2017016244A patent/MX371034B/es active IP Right Grant
- 2016-06-27 PL PL19165726T patent/PL3539961T3/pl unknown
- 2016-06-27 JP JP2017567737A patent/JP6997627B2/ja active Active
- 2016-06-27 RS RS20220005A patent/RS62781B1/sr unknown
- 2016-06-27 DK DK16733459.8T patent/DK3313838T3/da active
- 2016-06-27 LT LTEP19165726.1T patent/LT3539961T/lt unknown
- 2016-06-28 AR ARP160101956A patent/AR105179A1/es unknown
- 2016-06-28 TW TW105120362A patent/TWI723028B/zh active
-
2017
- 2017-12-06 US US15/833,277 patent/US10717746B2/en active Active
- 2017-12-12 DO DO2017000295A patent/DOP2017000295A/es unknown
- 2017-12-18 IL IL256393A patent/IL256393B/en unknown
- 2017-12-20 SV SV2017005598A patent/SV2017005598A/es unknown
- 2017-12-21 CL CL2017003306A patent/CL2017003306A1/es unknown
- 2017-12-22 NI NI201700174A patent/NI201700174A/es unknown
- 2017-12-28 CO CONC2017/0013713A patent/CO2017013713A2/es unknown
-
2018
- 2018-01-26 ZA ZA2018/00563A patent/ZA201800563B/en unknown
- 2018-09-25 DO DO2018000207A patent/DOP2018000207A/es unknown
-
2019
- 2019-06-19 CY CY20191100636T patent/CY1122111T1/el unknown
-
2020
- 2020-07-17 US US16/931,786 patent/US11352369B2/en active Active
-
2021
- 2021-12-22 CY CY20211101125T patent/CY1125066T1/el unknown
-
2022
- 2022-04-27 US US17/660,935 patent/US20220340592A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522869A5 (enExample) | ||
| HRP20190748T1 (hr) | Derivati policikličkog amida kao inhibitori cdk9 | |
| JP2017503867A5 (enExample) | ||
| CN103096718B (zh) | 可溶性鸟苷酸环化酶活化剂 | |
| KR102319857B1 (ko) | P2x7 조절제 | |
| KR102021159B1 (ko) | 트리시클릭 헤테로시클릭 화합물 및 jak 저해제 | |
| CN102711476B (zh) | 新的三环化合物 | |
| JP2019535664A5 (enExample) | ||
| NZ623922A (en) | Novel tricyclic compounds | |
| JP2013523884A5 (enExample) | ||
| JP2009507032A (ja) | 新規なイミダゾ系複素環 | |
| JP2016523270A5 (enExample) | ||
| JP2009529047A5 (enExample) | ||
| JP2013515729A5 (enExample) | ||
| JP2014531458A5 (enExample) | ||
| NZ601128A (en) | Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor | |
| JP2007519694A5 (enExample) | ||
| RU2019133777A (ru) | Гетероароматические соединения, пригодные в терапии | |
| CN120858096A (zh) | 双环衍生物及其组合物和应用 | |
| RU2017106489A (ru) | 6,7-дигидропиразоло[1,5-а]пиразин-4(5h)-оновые соединения и их применение в качестве отрицательных аллостерических модуляторов рецепторов mglur2 | |
| JP2014528436A5 (enExample) | ||
| AU2013365827A1 (en) | Tricyclic compounds as CFTR inhibitors | |
| AU2016371387B2 (en) | Tricyclic compounds and compositions as kinase inhibitors | |
| JP2016517877A5 (enExample) | ||
| JP2013518823A5 (enExample) |